Toronto-Dominion Bank vs 22nd Century Group Inc — how do they compare? Toronto-Dominion Bank trades at $120.27 (market cap $197.03B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Toronto-Dominion Bank is far larger — about 132234.9× 22nd Century Group Inc's market cap, and Toronto-Dominion Bank pays a 2.62% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| TD | XXII | |
|---|---|---|
Market Cap | $197.03B | $1.49M |
Sector | Financials | Technology |
52-Week High | $124.80 | $1.07K |
52-Week Low | $72.55 | $3.90 |
Dividend Yield | 2.62% | — |
Enterprise Value | — | -$6.74M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $4.32, down 0.23% with bearish technical signals. The company shows negative profitability with -65.76% net income margin and -130.19% ROE, though valuation ratios appear low with P/S of 0.03. Recent corporate actions include a 20:1 reverse stock split in June 2026. The company is expanding VLN product distribution in key markets including California and New York, supported by positive FDA regulatory developments.
While analyst consensus is 75% buy-rated, fundamental challenges persist with consistent revenue declines and negative cash flow from operations. Investment opportunity lies in successful VLN brand expansion and regulatory approvals, but risks include ongoing losses, competitive tobacco market pressures, and execution uncertainty in scaling reduced-nicotine products.
Trailing returns across standard periods
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →